Bromessigsaeure-o-nitro-phenyl-ester | 24265-33-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: Bromessigsaeure-o-nitro-phenyl-ester
• 英文别名: Nitrophenyl bromoacetate；(2-nitrophenyl) 2-bromoacetate
• CAS: 24265-33-6
• 化学式: C₈H₆BrNO₄
• 分子量: 260.044
• InChiKey: CKAZSKSYBMVOQT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  二甲基硫 、 Bromessigsaeure-o-nitro-phenyl-ester 生成 α-Dimethylsulfonio-essigsaeure-o-nitro-phenylesterbromid
  参考文献：
  名称：

  Carbanion mechanism of ester hydrolysis. II. o-Nitrophenyl .alpha.-cyano- and .alpha.-dimethylsulfonioacetate esters

  摘要：

  DOI：

  10.1021/ja01039a030
• 作为产物：
  描述：

  溴乙酸 、 硝苯酚 在 N,N'-二环己基碳二亚胺 作用下， 生成 Bromessigsaeure-o-nitro-phenyl-ester
  参考文献：
  名称：

  Electrostatic catalysis. II. Comparison of spontaneous and alkaline hydrolytic rate constants for .alpha.-substituted o-nitrophenyl esters

  摘要：

  DOI：

  10.1021/ja01039a027

文献信息

• [EN] ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE<br/>[FR] CONJUGUÉS ANIONIQUES D'UN MÉTABOLITE BACTÉRIEN GLYCOSYLÉ
  申请人：GLYCAN BIOSCIENCES PTY LTD

  公开号：WO2010037179A1

  公开（公告）日：2010-04-08

  The invention relates to anionic conjugates of glycosylated bacterial metabolites that may be used to mimic the structure and/or activity of the anionic bioactive molecules known as glycosaminoglycans (GAGs). The invention also relates to processes for the preparation of the conjugates. Such conjugates are useful in the prophylaxis and/or treatment of disease conditions and in particular chronic disease conditions such as inflammatory (including allergic) diseases, metastatic cancers and infection by pathogenic agents including bacteria, viruses or parasites.

  该发明涉及与糖基化细菌代谢产物的阴离子结合物，可用于模拟被称为糖胺聚糖（GAGs）的阴离子生物活性分子的结构和/或活性。该发明还涉及制备这些结合物的过程。这些结合物在预防和/或治疗疾病条件方面具有用处，特别是慢性疾病条件，如炎症（包括过敏）疾病、转移性癌症和感染病原体（包括细菌、病毒或寄生虫）的情况。
• Antituberculosis Agents. V: α-[5-(5-Nitro-2-furyl)- 1,3,4-oxadiazol-2-ylthio]acethydrazide and Related Compounds
  作者：I. Mir、M.T. Siddiqui、A.M. Comrie

  DOI：10.1002/jps.2600800610

  日期：1991.6

  alpha-[5-(5-Nitro-2-furyl)-1,3,4-oxadiazol-2-ylthio]aceth ydrazide, alpha-[5-(5-nitro-2-furyl)-1,3,4-oxadiazol-2-ylthio]acetamid e, delta-allyl-1-[( 5-(5-nitro-2-furyl)-1,3,4-oxadiazol-2-ylthio]acety) thiosemicarbazide, and other related compounds have been synthesised for testing against Mycobacterium tuberculosis.

  α-[5-（5-硝基-2-呋喃基）-1,3,4-恶二唑-2-基硫基]乙酰基吡嗪，α-[5-（5-硝基-2-呋喃基）-1,3,4 -恶二唑-2-基硫基]乙酰胺，δ-烯丙基-1-[[（5-（5-硝基-2-呋喃基）-1,3,4-恶二唑-2-基硫基]乙氧基]硫代氨基脲和其他相关化合物已合成用于结核分枝杆菌测试的药物。
• Engineered antibody fragment that irreversibly binds an antigen
  申请人：Meares F. Claude

  公开号：US20060063209A1

  公开（公告）日：2006-03-23

  The present invention provides mutant antibodies with infinite affinity for a target antigen. The antibodies comprise a mutant amino acid at a position within or proximate to a complimentarity determining region of the antibody and a linker covalently bound to the mutant amino acid, the linker comprising a reactive functional group. Subsequent to binding an antigen, the reactive functional group is converted to a covalent bond by reaction with a group of complementary reactivity on the bound antigen. The invention also provides bispecific antibodies with infinite binding affinity that comprise a second domain that specifically binds a metal chelate. The invention further provides methods of using such antibodies to diagnose and treat diseases and conditions.

  本发明提供了对目标抗原具有无限亲和力的突变抗体。这种抗体包括位于抗体互补决定区内或附近位置的突变氨基酸，以及与突变氨基酸共价结合的连接体，连接体包括反应性官能团。在结合抗原后，活性官能团通过与结合抗原上的互补反应基团反应转化为共价键。本发明还提供了具有无限结合亲和力的双特异性抗体，该抗体包含第二个结构域，可特异性结合金属螯合物。本发明进一步提供了使用这种抗体诊断和治疗疾病和病症的方法。
• Jacobs; Heidelberger, Journal of Biological Chemistry, 1915, vol. 21, p. 445
  作者：Jacobs、Heidelberger

  DOI：——

  日期：——
• ENGINEERED ANTIBODY FRAGMENT THAT IRREVERSIBLY BINDS AN ANTIGEN
  申请人：The Regents of the University of California

  公开号：EP1789087A2

  公开（公告）日：2007-05-30